CorMedix Competitors and Similar CompaniesClear all
CorMedix's competitors and similar companies include Veloxis Pharmaceuticals, European Medical Solutions, Oncologie and Hoth Therapeutics.
 CorMedix CorMedix is a pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and kidney disease. |  Veloxis Pharmaceuticals Veloxis Pharmaceuticals is a biopharmaceutical company that identifies, develops, and commercializes products used in transplantation and adjacent therapies. |  European Medical Solutions European Medical Solutions (formerly known as ASIT Biotech) is a clinical-stage biopharmaceutical company that focuses on the research, development, and commercialization of immunotherapy products for the treatment of allergies. |  Hoth Therapeutics Hoth Therapeutics operates as a biopharmaceutical company that develops therapeutics for patients suffering from atopic dermatitis. | ||
Founding Date | Founding Date 2006 | Founding Date 2002 | Founding Date 1997 | Founding Date 2018 | Founding Date N/A |
Type | Type Public | Type Subsidiary | Type Subsidiary | Type Private | Type Public |
Tags | |||||
Locations | Locations Berkeley Heights, US HQ | Locations København, DK HQ Cary, US Cary, US | Locations Liège, BE HQ Sint Lambrechts Woluwe, BE | Locations Waltham, US HQ Shanghai, CN Boston, US | Locations New York, US HQ |
Employees | Employees 3036% increase | Employees 54 | Employees 2630% increase | Employees 8 | Employees 2 |
Valuation ($) | Valuation ($) 749.2 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 6.7 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $311.7m (FY, 2025) | Revenue (est.) kr39.5m (FY, 2018) | Revenue (est.) €49.9m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods $22.1m (FY, 2025) | Cost of goods kr7.9m (FY, 2018) | Cost of goods €33.5m (FY, 2025) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $275.7m (FY, 2025) | Gross profit kr31.6m (FY, 2018) | Gross profit €17.5m (FY, 2025) | Gross profit N/A | Gross profit N/A |
Net income | Net income $163.1m (FY, 2025) | Net income (kr5.3m) (FY, 2018) | Net income €1.8m (FY, 2025) | Net income N/A | Net income ($12.5m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 11.5m | Total funding raised $ 60m | Total funding raised N/A | Total funding raised $ 96.5m | Total funding raised $ 3.7m |
For sources of this data, please see the company profile
View Company Profiles
Veloxis Pharmaceuticals
HQ
København, DK
Veloxis Pharmaceuticals is a biopharmaceutical company that identifies, develops, and commercializes products used in transplantation and adjacent therapies.
View companyEuropean Medical Solutions
HQ
Liège, BE
European Medical Solutions (formerly known as ASIT Biotech) is a clinical-stage biopharmaceutical company that focuses on the research, development, and commercialization of immunotherapy products for the treatment of allergies.
View companyHoth Therapeutics
HQ
New York, US
Employees
2
Hoth Therapeutics operates as a biopharmaceutical company that develops therapeutics for patients suffering from atopic dermatitis.
View company